Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: A case report  by Mubki, Thamer
Available online at www.sciencedirect.com
www.jdds.orgScienceDirect
Journal of Dermatology & Dermatologic Surgery 20 (2016) 87–90Case report
Platelet-rich plasma combined with intralesional triamcinolone
acetonide for the treatment of alopecia areata: A case report
Thamer Mubki ⇑
Department of Dermatology, College of Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
Received 14 August 2015; accepted 15 November 2015
Available online 24 November 2015Abstract
Treatment of long standing alopecia areata can be extremely diﬃcult. Combining more than one treatment modality may be needed.
Promising results have been previously reported using platelet-rich plasma. However, combining this treatment modality with other ther-
apies has never been evaluated. We report a patient with long standing alopecia areata treated with a combination of triamcinolone ace-
tonide and platelet-rich plasma intradermal injections. The trial was performed in a half-head design. One half of the scalp was treated
with both platelet-rich plasma and intralesional triamcinolone acetonide. The other half received intralesional triamcinolone acetonide
only. The half head treated with the combined therapy showed more regrowing hairs and larger hair ﬁber diameter. Our limited ﬁndings
suggest that combining platelet-rich plasma with intradermal triamcinolone acetonide may have a positive synergistic eﬀect for treating
alopecia areata. Controlled studies with a large number of patients are needed.
 2015 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Alopecia areata (AA) is a common autoimmune disease
that causes non scarring hair loss. It occurs in a patchy,
conﬂuent or diﬀuse pattern (Alkhalifah et al., 2010).
Although spontaneous remission is common, long standing
disease has a poor prognosis and is less likely to remit
spontaneously (Alkhalifah et al., 2010). Platelet-rich
plasma (PRP) has been previously used to treat a variety
of alopecias including AA with variable success rateshttp://dx.doi.org/10.1016/j.jdds.2015.11.002
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Production and hosting by Elsevier(Li et al., 2012). Herein we report, for the ﬁrst time, on
the use of PRP in combination with intralesional triamci-
nolone acetonide (TrA) for the treatment of long standing
AA.2. Report
A 22 year old healthy female presented to the dermatol-
ogy clinic complaining of diﬀuse scalp hair thinning started
5 years ago. The patient experienced patchy hair shedding
at the onset. Although, a partial hair regrowth was noted
a few months later, the total hair density was never back
to normal. Physical examination revealed diﬀuse scalp hair
thinning which was more pronounced on both temporal
and occipital areas. A 4 mm punch skin biopsy was per-
formed from the parietal scalp and showed variable inﬂam-
matory lymphocytic inﬁltrate surrounding the miniaturized
hair follicles with a marked reduction in the terminal–vellusehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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alopecia areata was made.
Previous treatments included topical clobetasol propi-
onate 0.05% scalp solution, minoxidil 2% solution and
anthralin 2% cream. Only partial hair regrowth was noted.
However, she had been oﬀ all treatments for the last
3 years. A written informed consent was obtained and the
trial was performed according to the Declaration of
Helsinki.
The right half of the scalp was treated with both TrA
(2.5 mg/ml, total of 4 ml) and intradermal injections of
PRP (2–3 ml). The left half was only treated with intrale-
sional injections of TrA (2.5 mg/ml, total of 4 ml). Treat-
ments were performed using hypodermic syringes with 30
gauge needles. Multiple intradermal injections in a linear
pattern, (1 cm) apart, were given and 0.1 ml was injected
at each injection site.
In total, eight treatment sessions were performed during
16 weeks on the right half of the scalp; 4 PRP treatment
sessions were alternated with 4 TrA treatment sessions at
2 week intervals. The left half of the scalp received only 4
TrA treatment sessions at 4 week intervals.
For PRP preparation, autologous blood (18 ml) was
taken from the patient and put into vacutainers (Pure
PRP System, Seoul, Korea) containing ACD-A (trisodium
citrate, citric acid and dextrose). The tube was centrifuged
at 1500G for 4 min. The PRP fraction was separated and
suspended with calcium chloride.
The treatment outcomes were analyzed using global
photography and digital trichoscopy. Two square areas,
each measuring 1  1 cm, were marked over both the right
and left parietal scalp, each in mid-pupillary line, 10 cm
proximal to the corresponding eyebrow. For each half of
the scalp, hair density and mean hair ﬁber diameter were
performed in the corresponding square using digital tri-
choscopy. The patient was evaluated at two time points:
T0; (week 0) and T1; two weeks after the last treatment
(week 16).
After completing the trial, both treatment modalities;
(TrA and PRP) and (TrA only), resulted in an increase in
the number of terminal hairs as compared to the baseline
(16% and 12% respectively). On the other hand, only the
(TrA and PRP) treated half showed an increase in the
mean hair shaft diameter (+35%) as compared to a decline
by (4%) in the (TrA only) treated half of the scalp.
Table 1.
Changes in the overall scalp hair coverage was minimal
(<25%) in both halves of the scalp as assessed by globalTable 1
Changes in the hair count and the hair shaft diameter at baseline; week 0 (T0
T0 T1 Cha
Hair count
Right half 19 hairs/cm2 22 hairs/cm2 +16
Left half 25 hairs/cm2 28 hairs/cm2 +12photography. However, the right half (TrA and PRP)
showed slightly better improvement. Figs. 1 and 2.
3. Discussion
In this case report, we have shown that combining PRP
with TrA leads to better improvement, mainly in regard to
trichological parameters; hair density and hair ﬁber diam-
eter, of AA as compared to using TrA only. Although only
a minimal diﬀerence (4%) in the number of re-growing ter-
minal hairs was noted between the two treatment methods,
the mean hair ﬁber diameter showed a more recognizable
diﬀerence (39%). Spontaneous remission has been reported
in up to 50% of AA patients at year 1 (Alkhalifah et al.,
2010). However in this particular case, these ﬁgures are
believed to be lower as this patient has suﬀered from AA
for 5 years.
This is the ﬁrst report to describe a possible synergistic
eﬀect of PRP when used in combination with TrA for treat-
ing long standing AA. The half-head design of this trial
helps to possibly eliminate other treatment variables.
PRP is an autologous preparation of growth-factor-rich
platelets in concentrated plasma (Li et al., 2012). More
than 20 diﬀerent growth factors, including platelet-
derived growth factor (PDGF), transforming growth factor
beta (TGFB), vascular endothelial growth factor (VEGF),
and ﬁbroblast growth factor (FGF), have been found in
PRP (Li et al., 2012; Arshdeep, 2014). These diﬀerent
growth factors are capable of promoting cell proliferation
and diﬀerentiation (Arshdeep, 2014; Takikawa et al.,
2011). Therefore, PRP has found many applications in
orthopedics, dentistry, dermatology, esthetics and wound
healing.
Mechanisms by which, the growth factors containing
PRP promote hair follicle growth and diﬀerentiation were
studied. In vivo studies have demonstrated the role of
PDGF signaling in the development of the hair canal
(Khatu et al., 2014). Similarly, FGF was found, in vitro,
to promote the proliferation of the dermal papilla cells
which play a key role in elongating the hair shafts (Li
et al., 2012). FGF-7 and beta-catenin; growth factors
known for stimulating the hair follicle growth; were both
up-regulated after administrating PRP (Li et al., 2012).
Moreover, activated PRP, both in vivo and in vitro, were
found to increase Bcl-2 protein levels. The latter has an
anti-apoptotic eﬀect on dermal papilla cells (Li et al., 2012).
PRP was also found to have a potent anti-inﬂammatory
eﬀect. It suppresses cytokine release and limits local tissue) and at 2 weeks after the last treatment; week 16 (T1).
nge% T0 T1 Change%
Hair shaft diameter
% 0.052 mm 0.070 mm +35%
% 0.052 mm 0.050 mm 4%
Figure 1. Right half of the scalp (PRP and TrA). (A) Before treatment. (B) After treatment.
Figure 2. Left half of the scalp (TrA only). (A) Before treatment. (B) After treatment.
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treating inﬂammatory hair conditions such as AA (El-
Sharkawy et al., 2007).
The use of PRP to treat a variety of scalp and hair con-
ditions was previously reported. PRP was used to enhance
the survival of the transplanted follicular grafts in hair
transplantation. A signiﬁcant increase in the number of
the growing follicular units was observed after immersing
the harvested grafts in PRP for 15 min before transplanta-
tion (Uebel et al., 2006). Moreover, intradermal PRP injec-
tion has been successfully used in patients with
androgenetic alopecia who failed to respond to moderately
long (6 months) treatment courses of ﬁnasteride and
minoxidil. In the latter, a signiﬁcant increase in the hair
density and a moderate improvement in scalp hair coverage
as measured by the global photography was observed after
3 months (Khatu et al., 2014). PRP mesotherapy proved to
be eﬀective in reducing hair loss and improving global hair
coverage in a non-controlled study involving 42 patients
with androgenetic alopecia (Betsi et al., 2014).
PRP as a monotherapy was also used to treat AA. In a
randomised double blind study, PRP was superior to both
TrA and placebo in the treatment of long standing recurrent
AA (Trink et al., 2013). Changes in the SALT score
were statistically signiﬁcant in favor of the PRP treatment.Additionally, PRP also reduced the number of dystrophic
hair as assessed by dermoscopy. Our report further con-
ﬁrms the previous observation, as combined TrA and
PRP proved superior to TrA in terms of the number of
regrowing terminal hairs and the hair ﬁber diameter, how-
ever, we observed only a minimal diﬀerence between PRP-
and non-PRP treated sites using global photography. We
believe that treatment of long standing AA requires a longer
treatment period than that of acute AA.
We propose that PRP could have a positive synergistic
eﬀect when used in combination with TrA for the treat-
ment of AA. This limited single case report does not
aim at providing conclusive evidence for the usefulness
of this novel combination therapy for treating long stand-
ing AA, rather it aims to promote further research and
conducting more controlled trials with a large number
of subjects.
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